$INO
INOVIO PHARMACEUTICALS, INC.

2013 Q4 Form 10-K Financial Statement

#000105572615000003 Filed on March 16, 2015

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2013 Q2
Revenue $1.740M $9.487M $785.6K
YoY Change 53.31% 1009.97% 80.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.980M $3.280M $2.900M
YoY Change 36.3% 59.22% 40.1%
% of Gross Profit
Research & Development $6.404M $5.438M $4.411M
YoY Change 44.14% 9.37% -2.56%
% of Gross Profit
Depreciation & Amortization $650.0K $480.0K $480.0K
YoY Change 30.0% -2.04% -4.0%
% of Gross Profit
Operating Expenses $9.744M $8.721M $6.458M
YoY Change 32.35% 22.03% -10.61%
Operating Profit -$8.004M $765.6K -$5.672M
YoY Change 28.53% -112.17% -16.44%
Interest Expense -$7.460M -$31.66M -$5.250M
YoY Change -234.17% 9211.76% -298.86%
% of Operating Profit -4135.08%
Other Income/Expense, Net
YoY Change
Pretax Income -$15.47M -$30.89M -$10.87M
YoY Change 2208.96% 365.91% 162.56%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.45M -$30.88M -$10.85M
YoY Change 2246.0% 366.28% 162.57%
Net Earnings / Revenue -888.35% -325.48% -1381.42%
Basic Earnings Per Share -$0.30 -$0.64 -$0.24
Diluted Earnings Per Share -$0.30 -$0.64 -$0.24
COMMON SHARES
Basic Shares Outstanding 52.13M shares 47.99M shares 44.99M shares
Diluted Shares Outstanding 52.13M shares 47.99M shares 44.99M shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.60M $46.20M $23.50M
YoY Change 283.94% 205.96% 21.13%
Cash & Equivalents $33.72M $33.07M $10.35M
Short-Term Investments $18.90M $13.10M $13.10M
Other Short-Term Assets $2.800M $1.100M $1.600M
YoY Change 86.67% -8.33% 14.29%
Inventory
Prepaid Expenses
Receivables $3.302M $10.57M $540.3K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $58.68M $57.85M $25.54M
YoY Change 267.51% 242.33% 19.89%
LONG-TERM ASSETS
Property, Plant & Equipment $2.887M $2.291M $348.1K
YoY Change 695.15% 472.64% -12.97%
Goodwill $10.11M $10.11M $10.11M
YoY Change 0.0%
Intangibles $5.719M $6.157M $6.596M
YoY Change -23.64%
Long-Term Investments $9.700M $11.10M $7.800M
YoY Change -9.35% 33.73% 4.0%
Other Assets $402.1K $171.0K $197.1K
YoY Change 199.62% -78.63% -75.36%
Total Long-Term Assets $29.60M $30.16M $25.46M
YoY Change 1.48% 9.28% -6.75%
TOTAL ASSETS
Total Short-Term Assets $58.68M $57.85M $25.54M
Total Long-Term Assets $29.60M $30.16M $25.46M
Total Assets $88.29M $88.02M $50.99M
YoY Change 95.59% 97.79% 4.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.000M $4.500M $3.400M
YoY Change 76.47% 40.63% -5.56%
Accrued Expenses $1.446M $1.359M $1.732M
YoY Change 2.87% -2.92% 44.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.97M $20.44M $19.07M
YoY Change 245.8% 80.87% 86.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.200M $5.200M $2.100M
YoY Change 264.71% 188.89% 10.53%
Total Long-Term Liabilities $6.200M $5.200M $2.100M
YoY Change 264.71% 188.89% 10.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.97M $20.44M $19.07M
Total Long-Term Liabilities $6.200M $5.200M $2.100M
Total Liabilities $35.38M $25.80M $21.32M
YoY Change 244.16% 88.31% 66.57%
SHAREHOLDERS EQUITY
Retained Earnings -$295.8M -$280.3M -$249.5M
YoY Change 28.74%
Common Stock $52.58K $207.6K $180.1K
YoY Change -63.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.46M $61.76M $29.20M
YoY Change
Total Liabilities & Shareholders Equity $88.29M $88.02M $50.99M
YoY Change 95.59% 97.79% 4.92%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2013 Q2
OPERATING ACTIVITIES
Net Income -$15.45M -$30.88M -$10.85M
YoY Change 2246.0% 366.28% 162.57%
Depreciation, Depletion And Amortization $650.0K $480.0K $480.0K
YoY Change 30.0% -2.04% -4.0%
Cash From Operating Activities $880.0K -$5.710M -$5.420M
YoY Change -115.91% -5.31% 2.07%
INVESTING ACTIVITIES
Capital Expenditures $70.00K -$180.0K -$30.00K
YoY Change -450.0% 800.0% -70.0%
Acquisitions
YoY Change
Other Investing Activities -$4.820M $0.00 -$4.290M
YoY Change -292.8% -100.0% -1816.0%
Cash From Investing Activities -$4.750M -$180.0K -$4.320M
YoY Change -291.53% -105.22% -3423.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.520M 28.60M 10.00K
YoY Change 10.24% 2225.2%
NET CHANGE
Cash From Operating Activities 880.0K -5.710M -5.420M
Cash From Investing Activities -4.750M -180.0K -4.320M
Cash From Financing Activities 4.520M 28.60M 10.00K
Net Change In Cash 650.0K 22.71M -9.730M
YoY Change -38.1% -1782.22% 87.84%
FREE CASH FLOW
Cash From Operating Activities $880.0K -$5.710M -$5.420M
Capital Expenditures $70.00K -$180.0K -$30.00K
Free Cash Flow $810.0K -$5.530M -$5.390M
YoY Change -114.7% -7.99% 3.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001055726
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60741082 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q2 dei Entity Public Float
EntityPublicFloat
614635315 USD
CY2014 dei Entity Registrant Name
EntityRegistrantName
INOVIO PHARMACEUTICALS, INC.
CY2014Q1 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-505926 USD
CY2014Q2 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
824390 USD
CY2013Q2 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-2032051 USD
CY2013Q3 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
3248926 USD
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 ino Adjustmentfor Changein Fair Valueof Warrant Liability
AdjustmentforChangeinFairValueofWarrantLiability
0 USD
CY2013 ino Adjustmentfor Changein Fair Valueof Warrant Liability
AdjustmentforChangeinFairValueofWarrantLiability
0 USD
CY2014 ino Adjustmentfor Changein Fair Valueof Warrant Liability
AdjustmentforChangeinFairValueofWarrantLiability
-2181203 USD
CY2013 ino Cashless Exerciseof Warrants Value
CashlessExerciseofWarrantsValue
0 USD
CY2014 ino Cashless Exerciseof Warrants Value
CashlessExerciseofWarrantsValue
0 USD
CY2012 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
1982620 USD
CY2013Q1 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-1427616 USD
CY2013Q2 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-3199878 USD
CY2013Q3 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-34952210 USD
CY2013Q4 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-6052965 USD
CY2013 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-45632669 USD
CY2014Q3 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
-113980 USD
CY2014Q4 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
143659 USD
CY2014 ino Change In Fair Value Of Common Stock Warrants
ChangeInFairValueOfCommonStockWarrants
348143 USD
CY2012 ino Change In Value Of Common Stock Warrants
ChangeInValueOfCommonStockWarrants
-1982620 USD
CY2013 ino Change In Value Of Common Stock Warrants
ChangeInValueOfCommonStockWarrants
45632669 USD
CY2014 ino Change In Value Of Common Stock Warrants
ChangeInValueOfCommonStockWarrants
-348143 USD
CY2012 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
1631819 USD
CY2013Q1 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-836084 USD
CY2013Q4 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-1419536 USD
CY2013 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-1038745 USD
CY2014Q1 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-376963 USD
CY2014Q2 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-1458160 USD
CY2014Q3 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
1168911 USD
CY2014Q4 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
3342436 USD
CY2014 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
2676224 USD
CY2013 ino Changein Classificationof Warrantsfrom Liabilityto Equity Dueto Exercise
ChangeinClassificationofWarrantsfromLiabilitytoEquityDuetoExercise
35370529 USD
CY2014 ino Changein Classificationof Warrantsfrom Liabilityto Equity Dueto Exercise
ChangeinClassificationofWarrantsfromLiabilitytoEquityDuetoExercise
17002211 USD
CY2014Q3 ino Classof Warrantor Right Numberof Securities Calledby Warrantsor Rights Warrants Expired
ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRightsWarrantsExpired
83334 shares
CY2014 ino Convertible Preferred Stock Shares Issued Upon Conversion Conversion Price Per Share
ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
27.20
CY2013Q4 ino Deferred Revenue From Affiliated Entity Current
DeferredRevenueFromAffiliatedEntityCurrent
388542 USD
CY2014Q4 ino Deferred Revenue From Affiliated Entity Current
DeferredRevenueFromAffiliatedEntityCurrent
394791 USD
CY2013Q4 ino Deferred Revenue From Affiliated Entity Noncurrent
DeferredRevenueFromAffiliatedEntityNoncurrent
1211694 USD
CY2014Q4 ino Deferred Revenue From Affiliated Entity Noncurrent
DeferredRevenueFromAffiliatedEntityNoncurrent
836694 USD
CY2012 ino Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
405000 USD
CY2013 ino Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
338000 USD
CY2014 ino Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
728000 USD
CY2012 ino Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
-124000 USD
CY2013 ino Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
605000 USD
CY2014 ino Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits
EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
-749000 USD
CY2013 ino Exercise Of Stock Options And Warrants For Cash
ExerciseOfStockOptionsAndWarrantsForCash
19808232 USD
CY2012 ino Income Tax Reconciliation Fair Value Warrant
IncomeTaxReconciliationFairValueWarrant
-811000 USD
CY2013 ino Income Tax Reconciliation Fair Value Warrant
IncomeTaxReconciliationFairValueWarrant
16129000 USD
CY2014 ino Income Tax Reconciliation Fair Value Warrant
IncomeTaxReconciliationFairValueWarrant
-180000 USD
CY2012 ino Income Tax Reconciliation Statute Limitations
IncomeTaxReconciliationStatuteLimitations
190000 USD
CY2014 ino Exercise Of Stock Options And Warrants For Cash
ExerciseOfStockOptionsAndWarrantsForCash
13252543 USD
CY2013 ino Fair Value Of Common Stock Warrants Issued In Connection With Equity Financing
FairValueOfCommonStockWarrantsIssuedInConnectionWithEquityFinancing
-5968244 USD
CY2013Q4 ino Goodwill And Intangible Assets Gross
GoodwillAndIntangibleAssetsGross
29731244 USD
CY2014Q4 ino Goodwill And Intangible Assets Gross
GoodwillAndIntangibleAssetsGross
29731244 USD
CY2013Q4 ino Goodwill And Intangible Assets Net
GoodwillAndIntangibleAssetsNet
15832149 USD
CY2014Q4 ino Goodwill And Intangible Assets Net
GoodwillAndIntangibleAssetsNet
14889430 USD
CY2012 ino Impairment Of Long Term Investments
ImpairmentOfLongTermInvestments
0 USD
CY2013 ino Impairment Of Long Term Investments
ImpairmentOfLongTermInvestments
38950 USD
CY2014 ino Impairment Of Long Term Investments
ImpairmentOfLongTermInvestments
33990 USD
CY2013 ino Income Tax Reconciliation Statute Limitations
IncomeTaxReconciliationStatuteLimitations
-735000 USD
CY2014 ino Income Tax Reconciliation Statute Limitations
IncomeTaxReconciliationStatuteLimitations
-849000 USD
CY2012 ino Increase Decrease In Deferred Revenue From Related Parties
IncreaseDecreaseInDeferredRevenueFromRelatedParties
-375000 USD
CY2013 ino Increase Decrease In Deferred Revenue From Related Parties
IncreaseDecreaseInDeferredRevenueFromRelatedParties
-375000 USD
CY2014 ino Increase Decrease In Deferred Revenue From Related Parties
IncreaseDecreaseInDeferredRevenueFromRelatedParties
-368751 USD
CY2012 ino Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
445981 USD
CY2013 ino Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
1401258 USD
CY2014 ino Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
-674975 USD
CY2012 ino Interest Income Accrued On Short Term Investments Certificates Of Deposit
InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
-1147 USD
CY2013 ino Interest Income Accrued On Short Term Investments Certificates Of Deposit
InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
-484 USD
CY2014 ino Interest Income Accrued On Short Term Investments Certificates Of Deposit
InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
0 USD
CY2012 ino Issuance Of Common Stock And Warrants For Cash Financing Costs
IssuanceOfCommonStockAndWarrantsForCashFinancingCosts
USD
CY2014 ino Issuance Of Common Stock And Warrants For Cash Financing Costs
IssuanceOfCommonStockAndWarrantsForCashFinancingCosts
0 USD
CY2013 ino Issuance Of Common Stock And Warrants For Cash Net Of Financing Costs
IssuanceOfCommonStockAndWarrantsForCashNetOfFinancingCosts
14274819 USD
CY2012 ino Issuance Of Common Stock For Cash Financing Costs
IssuanceOfCommonStockForCashFinancingCosts
164695 USD
CY2013 ino Issuance Of Common Stock For Cash Financing Costs
IssuanceOfCommonStockForCashFinancingCosts
585000 USD
CY2014 ino Issuance Of Common Stock For Cash Financing Costs
IssuanceOfCommonStockForCashFinancingCosts
4000000 USD
CY2014Q4 ino Maximum Amountof Additional Equity Fundraising
MaximumAmountofAdditionalEquityFundraising
10000000 USD
CY2014Q4 ino Operating Loss Carryforwards Amount Relatedto Excess Sharebased Compensation
OperatingLossCarryforwardsAmountRelatedtoExcessSharebasedCompensation
1900000 USD
CY2014 ino Preferred Stock Conversion Daily Market Price Triggering Mandatory Conversion
PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion
72.00
CY2013Q4 ino Prepaid Expenses And Other Current Assets From Affiliated Entity
PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
2057350 USD
CY2014Q4 ino Prepaid Expenses And Other Current Assets From Affiliated Entity
PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
1382375 USD
CY2012 ino Proceedsfrom Stock Optionand Warrant Exercises
ProceedsfromStockOptionandWarrantExercises
0 USD
CY2013 ino Proceedsfrom Stock Optionand Warrant Exercises
ProceedsfromStockOptionandWarrantExercises
19808232 USD
CY2014 ino Proceedsfrom Stock Optionand Warrant Exercises
ProceedsfromStockOptionandWarrantExercises
13252543 USD
CY2014Q4 ino Receivablefromsaleof Intangible Assets
ReceivablefromsaleofIntangibleAssets
2000000 USD
CY2012 ino Recognition Amortization Of Deferred Tax Liabilities
RecognitionAmortizationOfDeferredTaxLiabilities
22806 USD
CY2013 ino Recognition Amortization Of Deferred Tax Liabilities
RecognitionAmortizationOfDeferredTaxLiabilities
32274 USD
CY2014 ino Recognition Amortization Of Deferred Tax Liabilities
RecognitionAmortizationOfDeferredTaxLiabilities
27537 USD
CY2012 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
577467 USD
CY2013Q1 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
106250 USD
CY2013Q2 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
106250 USD
CY2013Q3 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
106250 USD
CY2013Q1 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
14259 USD
CY2013Q2 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
14311 USD
CY2012 ino Transaction Costs Associated With Issuanceof Warrants
TransactionCostsAssociatedWithIssuanceofWarrants
0 USD
CY2013Q4 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
106250 USD
CY2013 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
425000 USD
CY2014Q1 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
116964 USD
CY2014Q2 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
137500 USD
CY2014Q3 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
112500 USD
CY2014Q4 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
112500 USD
CY2014 ino Revenue Under Collaborative Research And Development Arrangements With Affiliated Entity
RevenueUnderCollaborativeResearchAndDevelopmentArrangementsWithAffiliatedEntity
479464 USD
CY2012 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
82536 USD
CY2013Q3 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
8388760 USD
CY2013Q4 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
822217 USD
CY2013 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
9239547 USD
CY2014Q1 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
1435727 USD
CY2014Q2 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
3107781 USD
CY2014Q3 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
1114952 USD
CY2014Q4 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
1758108 USD
CY2014 ino Revenue Under Collaborative Researchand Development Arrangements
RevenueUnderCollaborativeResearchandDevelopmentArrangements
7416568 USD
CY2014 ino Share Based Compensation Arrangement By Share Based Payment Award Maximum Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
P10Y
CY2014 ino Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm
P4Y8M12D
CY2014 ino Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
18100000 USD
CY2014Q4 ino Sharebased Compensation Arrangementby Sharebased Payment Award Options Expectedto Vest Outstanding Number
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber
1191093 shares
CY2014 ino Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
-57187 USD
CY2014Q4 ino Tax Benefits Expired
TaxBenefitsExpired
27100000 USD
CY2013 ino Transaction Costs Associated With Issuanceof Warrants
TransactionCostsAssociatedWithIssuanceofWarrants
315970 USD
CY2014 ino Transaction Costs Associated With Issuanceof Warrants
TransactionCostsAssociatedWithIssuanceofWarrants
0 USD
CY2014Q4 ino Warrants Received During Period
WarrantsReceivedDuringPeriod
550000 USD
CY2013Q4 ino Weighted Average Price Per Share On Sale Of Common Stock
WeightedAveragePricePerShareOnSaleOfCommonStock
4.96
CY2014Q4 ino Working Capital
WorkingCapital
84900000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5444508 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6383170 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
5444508 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
6383170 USD
CY2013Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
1865723 USD
CY2014Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
2003091 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3301563 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2804207 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1446180 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2007432 USD
CY2013Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2586806 USD
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2982090 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1915428 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2541356 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-76365 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-251390 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
348267389 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
443327915 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1821170 USD
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1770537 USD
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
942719 USD
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9472381 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7658904 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5576939 shares
CY2013Q4 us-gaap Assets
Assets
88287207 USD
CY2014Q4 us-gaap Assets
Assets
131785097 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
58683589 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
98947084 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
18905608 USD
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
53075974 USD
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
560 USD
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2737 USD
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
78614 USD
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
254127 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
18983662 USD
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
53327364 USD
CY2013Q4 us-gaap Available For Sale Securities Equity Securities Noncurrent
AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
717500 USD
CY2014Q4 us-gaap Available For Sale Securities Equity Securities Noncurrent
AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
550000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17350116 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5646021 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33719796 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40543982 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11704095 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28073775 USD
CY2014Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
35 investment
CY2014Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
5 investment
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
7000 USD
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1000 USD
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000 USD
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000 USD
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-1000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6824186 USD
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3514817 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1012060 shares
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52576390 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60741082 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52576390 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60741082 shares
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
52577 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
60741 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19675011 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66233259 USD
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36315158 USD
CY2012 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-44025 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-55084 USD
CY2014 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-18420 USD
CY2012 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-19630986 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-66178175 USD
CY2014 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36296738 USD
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000 USD
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
20000 USD
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
15000 USD
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
18000 USD
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
23000 USD
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
32000 USD
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
27000 USD
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3013263 USD
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4709229 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1624388 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3187223 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1997333 USD
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
173779 USD
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
3000 USD
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
17000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1085000 USD
CY2014 us-gaap Depreciation
Depreciation
626554 USD
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
9000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
62146000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
77321000 USD
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2782000 USD
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2059000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1958000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
61839 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
342573 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
48846000 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
64354000 USD
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8641000 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8491000 USD
CY2013Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
1877000 USD
CY2014Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
2417000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
61061000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
75363000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
134000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
161000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1096000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
804000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Investment In Noncontrolled Affiliates
DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
123000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Investment In Noncontrolled Affiliates
DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
1315000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
195778 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
504049 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
170000 USD
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
196000 USD
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
275000 USD
CY2014 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2014 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2012 us-gaap Depreciation
Depreciation
173750 USD
CY2013 us-gaap Depreciation
Depreciation
328752 USD
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
522255 USD
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
28407 USD
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
772918 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
772918 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
775331 USD
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1984 USD
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
118 USD
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1689 USD
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
956000 USD
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5300000 USD
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M0D
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y0M0D
CY2014Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.2
CY2013 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2014 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2300000 USD
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
46100000 USD
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-516000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13899095 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14841814 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
768371 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
870200 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
816321 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19617873 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19617873 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5718778 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4776059 USD
CY2012 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1151000 USD
CY2013Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2013Q2 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2013Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2013Q4 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
1000000 USD
CY2013 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
2000000 USD
CY2014 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1822 USD
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2959 USD
CY2014 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
501000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10778359 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2974153 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3046586 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3282796 USD
CY2013Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4339539 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13643074 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4132218 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4347327 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3153714 USD
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4224429 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15857688 USD
CY2013Q4 us-gaap Goodwill
Goodwill
10113371 USD
CY2014Q4 us-gaap Goodwill
Goodwill
10113371 USD
CY2013Q4 us-gaap Goodwill Gross
GoodwillGross
10113371 USD
CY2014Q4 us-gaap Goodwill Gross
GoodwillGross
10113371 USD
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31000 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7415000 USD
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8819000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14235000 USD
CY2012 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
438000 USD
CY2013 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-623000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-60000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6894000 USD
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-23118000 USD
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12639000 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
603000 USD
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
279000 USD
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1573000 USD
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
42000 USD
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-12000 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
332000 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1234000 USD
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1651000 USD
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2362000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-790844 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2164045 USD
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1487072 USD
CY2012 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
166931 USD
CY2013 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
334980 USD
CY2014 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-493848 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
362524 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2471130 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-499176 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-2172 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-36234 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
1820 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
282048 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3179721 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-260719 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
14794 USD
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-26793 USD
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
72493 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-363584 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
229705 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
160540 USD
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
351 USD
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
352 USD
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-100762 USD
CY2012 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2013 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
280903 shares
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5718778 USD
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4776059 USD
CY2012 us-gaap Interest And Other Income
InterestAndOtherIncome
166113 USD
CY2013Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
39460 USD
CY2013Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
37391 USD
CY2013Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
46787 USD
CY2013Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
8576 USD
CY2013 us-gaap Interest And Other Income
InterestAndOtherIncome
132214 USD
CY2014Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
52076 USD
CY2014Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
68999 USD
CY2014Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
97174 USD
CY2014Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
113212 USD
CY2014 us-gaap Interest And Other Income
InterestAndOtherIncome
331461 USD
CY2012 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
0 USD
CY2013 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
0 USD
CY2014 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
54534 USD
CY2013Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
9664587 USD
CY2014Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
12340811 USD
CY2012Q4 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
0 USD
CY2013Q4 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
2538000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
35384524 USD
CY2014Q4 us-gaap Liabilities
Liabilities
20247503 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88287207 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131785097 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28966456 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14023752 USD
CY2012 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
0 USD
CY2013 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
0 USD
CY2014 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
-57187 USD
CY2013Q4 us-gaap Minority Interest
MinorityInterest
447659 USD
CY2014Q4 us-gaap Minority Interest
MinorityInterest
310618 USD
CY2014 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
0 USD
CY2013Q4 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.09
CY2014Q4 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.09
CY2014Q2 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
0.91
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5325141 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52691937 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72461725 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5275565 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9236843 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35812206 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22306785 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15381437 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29823644 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-19668955 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-8844120 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-10852588 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-30877410 USD
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-15454330 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-66028448 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-10821460 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-10711274 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7177575 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-7411404 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-36121713 USD
CY2012 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-44025 USD
CY2013Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14160 USD
CY2013Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14008 USD
CY2013Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13443 USD
CY2013Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13473 USD
CY2013 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-55084 USD
CY2014Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9408 USD
CY2014Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-6443 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1486 USD
CY2014Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1083 USD
CY2014 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-18420 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19668955 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66028448 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38302916 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
27612184 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
8089265 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
6457668 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
8721201 USD
CY2013Q4 us-gaap Operating Expenses
OperatingExpenses
9743544 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
33011678 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
12357698 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
13954608 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
10171519 USD
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
13468902 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
49952727 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-23493532 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6634040 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5672058 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
765644 USD
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8003878 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-19544332 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10000055 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10152946 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8331166 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11011794 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-39495961 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
13745000 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
621000 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1506000 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1275000 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1298000 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1323000 USD
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
7722000 USD
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
444000 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
906000 USD
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1200000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
991979 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1397989 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
402075 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
474568 USD
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1984 USD
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
118 USD
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1689 USD
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
35985 USD
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-149845 USD
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173336 USD
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
39000 USD
CY2014 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
34000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
240986 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176925 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1379980 USD
CY2012 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9142220 USD
CY2013 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
15399495 USD
CY2014 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
47185945 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
26 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
23 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
26 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
23 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
637433 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
797973 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5325141 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32883705 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59209182 USD
CY2012 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
650000 USD
CY2013 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
2000000 USD
CY2014 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 USD
CY2012 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
14008771 USD
CY2013 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
4339577 USD
CY2014 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
12753719 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1600000 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1400000 USD
CY2012 us-gaap Profit Loss
ProfitLoss
-19712980 USD
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-8858280 USD
CY2013Q2 us-gaap Profit Loss
ProfitLoss
-10866596 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-30890853 USD
CY2013Q4 us-gaap Profit Loss
ProfitLoss
-15467803 USD
CY2013 us-gaap Profit Loss
ProfitLoss
-66083532 USD
CY2014Q1 us-gaap Profit Loss
ProfitLoss
-10830868 USD
CY2014Q2 us-gaap Profit Loss
ProfitLoss
-10717717 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
-7179061 USD
CY2014Q4 us-gaap Profit Loss
ProfitLoss
-7412487 USD
CY2014 us-gaap Profit Loss
ProfitLoss
-36140133 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4801973 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7124560 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2886545 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4583204 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17984825 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5115112 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4411082 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5438405 USD
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6404005 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21368604 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8225480 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9607281 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7017805 USD
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9244473 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34095039 USD
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100762 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295788577 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-331910290 USD
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
3458649 USD
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
1334716 USD
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
665049 USD
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
991835 USD
CY2013Q4 us-gaap Revenue From Grants
RevenueFromGrants
811199 USD
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
3802799 USD
CY2014Q1 us-gaap Revenue From Grants
RevenueFromGrants
804952 USD
CY2014Q2 us-gaap Revenue From Grants
RevenueFromGrants
556381 USD
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
612901 USD
CY2014Q4 us-gaap Revenue From Grants
RevenueFromGrants
586500 USD
CY2014 us-gaap Revenue From Grants
RevenueFromGrants
2560734 USD
CY2012 us-gaap Revenues
Revenues
4118652 USD
CY2013Q1 us-gaap Revenues
Revenues
1455225 USD
CY2013Q2 us-gaap Revenues
Revenues
785610 USD
CY2013Q3 us-gaap Revenues
Revenues
9486845 USD
CY2013Q4 us-gaap Revenues
Revenues
1739666 USD
CY2013 us-gaap Revenues
Revenues
13467346 USD
CY2014Q1 us-gaap Revenues
Revenues
2357643 USD
CY2014Q2 us-gaap Revenues
Revenues
3801662 USD
CY2014Q3 us-gaap Revenues
Revenues
1840353 USD
CY2014Q4 us-gaap Revenues
Revenues
2457108 USD
CY2014 us-gaap Revenues
Revenues
10456766 USD
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
4118652 USD
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
13467346 USD
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
10456766 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1345613 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1868345 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
5428946 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
51875 shares
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1345613 USD
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1868345 USD
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5428946 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
52455024 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.52
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4134591 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4840514 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.84
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
124003 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
70517 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
140494 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.95
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1140859 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.88
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.76
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.19
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.63
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.32
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.32
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.95
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.52
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3545848 shares
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
4840514 shares
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14600000 USD
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.48
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
6.19
CY2014 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y9M7D
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
18905608 USD
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
53075974 USD
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
294442 shares
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5325141 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18924856 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59209182 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
111226976 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47861662 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
34857405 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
52902683 USD
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
111537594 USD
CY2014Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2012 us-gaap Straight Line Rent
StraightLineRent
15799 USD
CY2013 us-gaap Straight Line Rent
StraightLineRent
-410187 USD
CY2014 us-gaap Straight Line Rent
StraightLineRent
-762616 USD
CY2014Q4 us-gaap Tenant Improvements
TenantImprovements
933000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1829000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1896000 USD
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
19540583 USD
CY2014Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2022729 USD
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34127312 shares
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39038883 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44988704 shares
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44988704 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47989039 shares
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2416000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2759000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
72000 USD
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
305000 USD
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
331000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
-5000 USD
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
215000 USD
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
12000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
2400000 USD
CY2013Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52127419 shares
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46087773 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55159002 shares
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60474859 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60602831 shares
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60805871 shares
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59408252 shares
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34127312 shares
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39038883 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47989039 shares
CY2013Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52127419 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46087773 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55159002 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60232498 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60392911 shares
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60610367 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59127349 shares
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:10pt;"> Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.&#160; Inovio&#8217;s synthetic products are based on the Company&#8217;s SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;design.&#160; The Company has completed, current or planned clinical programs of its proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> products for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, and Ebola.&#160; The Company's partners and collaborators include F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (&#8220;Roche&#8221;), University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), United States Military HIV Research Program (&#8220;USMHRP&#8221;), U.S. Army Medical Research Institute of Infectious Diseases (&#8220;USAMRIID&#8221;), HIV Vaccines Trial Network (&#8220;HVTN&#8221;), &#160;Defense Advanced Research Projects Agency (&#8220;DARPA&#8221;) and MedImmune, LLC.&#160; Inovio is incorporated in Delaware.</font></div></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents, and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. The Company had contracts with customers which represented more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> of total revenues for all of the years presented as discussed in Note 6.</font></div></div>
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in accordance with United States generally accepted accounting principles requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Inovio bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, the Company reviews its estimates to ensure that these estimates appropriately reflect changes in the business or as new information becomes available.</font></div></div>

Files In Submission

Name View Source Status
0001055726-15-000003-index-headers.html Edgar Link pending
0001055726-15-000003-index.html Edgar Link pending
0001055726-15-000003.txt Edgar Link pending
0001055726-15-000003-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grapha02.jpg Edgar Link pending
ino-12312014x10k.htm Edgar Link pending
ino-12312014x10kex1012.htm Edgar Link pending
ino-12312014x10kex211.htm Edgar Link pending
ino-12312014x10kex231.htm Edgar Link pending
ino-12312014x10kex311.htm Edgar Link pending
ino-12312014x10kex312.htm Edgar Link pending
ino-12312014x10kex321.htm Edgar Link pending
ino-20141231.xml Edgar Link completed
ino-20141231.xsd Edgar Link pending
ino-20141231_cal.xml Edgar Link unprocessable
ino-20141231_def.xml Edgar Link unprocessable
ino-20141231_lab.xml Edgar Link unprocessable
ino-20141231_pre.xml Edgar Link unprocessable
inovio2007omnibusince_image1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending